1. G1. Gratchev AV, Sobenin IA, Orekhov AN, et al. Monocytes as a diagnostic marker of cardiovascular diseases. Immunobiology. 2012;217(5):476-82. doi: 10.1016/j.imbio.2012.01.008.
2. Chistiakov DA, Bobryshev YV, Orekhov AN. Macrophage-mediated cholesterol handling in atherosclerosis. J Cell Mol. Med. 2016;20(1):17-28. doi:10.1111/jcmm.12689.
3. Orekhov AN, Nikiforov NG, Elizova NV, et al. Phenomenon of individual difference in human monocyte activation. Exp. Mol. Pathol. 2015;99(1): 151-4. doi: 10.1016/j.yexmp.2015.06.011.
4. Gratchev A, Ovsiy I, Manousaridis I, et al. Novel Monocyte Biomarkers of Atherogenic Conditions. Curr. Pharm. Des. 2013;19(33)5859-64.
5. Varin A, Gordon S. Alternative activation of macrophages: immune function and cellular biology. Immunobiology. 2009;214:630-41. doi:10.1016/j.imbio.2008.11.009.
6. Brocheriou I, Maouche S, Durand H, et al. Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. Atherosclerosis. 2011;214:316-24. doi:10.1016/j.atherosclerosis.2010.11.023.
7. Stoger JL, Gijbels MJ, van der Velden S, et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis. 2012;225(2):461-8. doi: 10.1016/j.atherosclerosis.2012.09.013.
8. Cho KY, Miyoshi H, Kuroda S, et al. The phenotype of infiltrating macrophages influences arteriosclerotic plaque vulnerability in the carotid artery. J Stroke Cerebrovasc Dis. 2013;22(7):910-8. doi:10.1016/j.jstrokecerebrovasdis.2012.11.020.
9. Аладинский ВА, Никифоров НГ, Орехова МА и др. Прямая антиатеросклеротическая терапия: возможные подходы, результаты клинических исследований. Патол. физиол. и эксп. Тер. 2013;(4):76-83.
10. Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. Nat Rev Cardiol. 2015;12:10-7. doi:10.1038/nrcardio.2014.173.
11. Biswas SK, Chittezhath M, Shalova IN, et al. Macrophage polarization and plasticity in health and disease. Immunol Res. 2012;11-24. doi:10.1007/s12026-012-8291-9.
12. Bouhlel MA, Derudas B, Rigamonti E, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007;6:137-43.
13. Chinetti-Gbaguidi G, Baron M, Bouhlel MA, et al. Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARgamma and LXRalpha pathways. Circ Res. 2011;108:985-95. doi:10.1161/CIRCRESAHA.110.233775.
14. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15:104-16. doi:10.1038/nri3793.
15. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889-96. doi:10.1038/ni.1937.
16. da Silva RF, Lappalainen J, Lee-Rueckert M, Kovanen PT. Conversion of human M-CSF macrophages into foam cells reduces their proinflammatory responses to classical M1-polarizing activation. Atherosclerosis. 2016;248;170-8. doi:10.1016/j.atherosclerosis.2016.03.012.
17. Byron SA, van Keuren-Jensen KR, Engelthaler DM, et al. Translating RNA sequencing into clinical diagnostics: Opportunities and challenges. Nat. Rev. Genet. 2016;17:257-71. doi:10.1038/nrg.2016.10.
18. Barrans JD, Allen PD, Stamatiou D, et al. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am. J. Pathol. 2002;160:2035-43.
19. Malone JH, Oliver B. Microarrays, deep sequencing and the true measure of the transcriptome. BMC Biol. 2011;9:34. doi:10.1186/1741-7007-9-34.
20. Rienzo M, Casamassimi A, Schiano C, et al. Distinct alternative splicing patterns of mediator subunit genes during endothelial progenitor cell differentiation. Biochimie. 2012;94:1828-32. doi:10.1016/j.biochi.2012.04.008.
21. Murphy J, Bustin SA. Reliability of real-time reverse-transcription PCR in clinical diagnostics: Gold standard or substandard? Expert Rev. Mol. Diagn. 2009;9:187-97. doi:10.1586/14737159.9.2.187.
22. Cao L, Cui X, Hu J, et al. Advances in digital polymerase chain reaction (dPCR) and its emerging biomedical applications. Biosens. Bioelectron. 2017;90:459-74. doi:10.1016/j.bios.2016.09.082.
23. Rai G, Rai R, Saeidian AH, et al. Microarray to deep sequencing: transcriptome and miRNA profiling to elucidate molecular pathways in systemic lupus erythematosus. Immunol Res. 2016;64(1):14-24. doi:10.1007/s12026-015-8672-y.
24. Farkas MH, Grant GR, White JA, et al. Transcriptome analyses of the human retina identify unprecedented transcript diversity and 3.5 Mb of novel transcribed sequence via significant alternative splicing and novel genes. BMC Genomics. 2013;14:486. doi:10.1186/1471-2164-14-486.
25. Lyu Y, Yang Y, Liu Y, et al. Analysis of a patient with X-linked mental retardation by next generation sequencing. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2018;35(2):257-60. doi:10.3760/cma.j.issn.1003-9406.2018.02.025.
26. Kesherwani V, Shahshahan HR, Mishra PK. Cardiac transcriptome profiling of diabetic Akita mice using microarray and next generationsequencing. PLoS One. 2017; 12(8). doi:10.1371/journal.pone.0182828.eCollection 2017.
27. Martinez FO, Gordon S, Locati M, et al. Transcriptional profiling of the human monocyto-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol. 2006;177:7303-11.
28. Adamson S, Leitinger N. Phenotypic modulation of macrophages in response to plaque lipids. Curr Opin Lipidol. 2011;22:335-42. doi:101097/MOL.0b013e32834a97e4.
29. Zhang YP, Pan CS, Yan L, et al. Catalpol restores LPS-elicited rat microcirculation disorder by regulation of a network of signaling involving inhibition of TLR-4 and SRC. Am J Physiol Gastrointest Liver Physiol. 2016;311(6):G1091-G1104. doi:10.1152/ajpgi.00159.2016.